CAR‐T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment

Chimeric antigen receptor T cells (CAR‐T) have provided promising results in multiple myeloma (MM). However, many patients still relapse, pointing toward the need of improving this therapy. Here, we analyzed peripheral blood T cells from MM patients at different stages of the disease and investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Abecassis, Audrey, Roders, Nathalie, Fayon, Maxime, Choisy, Caroline, Nelson, Elisabeth, Harel, Stephanie, Royer, Bruno, Villesuzanne, Camille, Talbot, Alexis, Garrick, David, Goodhardt, Michele, Fermand, Jean‐Paul, Burbridge, Mike, Arnulf, Bertrand, Bories, Jean‐Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421998/
https://www.ncbi.nlm.nih.gov/pubmed/36051036
http://dx.doi.org/10.1002/jha2.479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421998/
https://www.ncbi.nlm.nih.gov/pubmed/36051036
http://dx.doi.org/10.1002/jha2.479

Ejemplares similares